Trial Profile
A Phase III Multicenter, Randomized, Double-Blind, Parallel Group Study to Evaluate the Safety and Efficacy of the 30 mg Intravenous Formulation of the Neurokinin-1 Receptor Antagonist GW679769 [casopitant] for Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 31 Aug 2023
Price :
$35
*
At a glance
- Drugs Casopitant (Primary) ; Ondansetron (Primary)
- Indications Postoperative nausea and vomiting
- Focus Therapeutic Use
- Sponsors GSK
- 15 Oct 2008 Actual start date changed from Dec 2005 to Mar 2006 as reported by Clinicaltrials.gov
- 12 Oct 2008 Actual start date changed from Apr 2006 to Dec 2005 as reported by Clinicaltrials.gov
- 19 Jul 2007 Status changed from recruiting to completed